Trygve Lofterød

  • Consultant; MD, PhD
 

Publications 2025

Gabrielsen E, Wilsgaard T, Frydenberg H, Lofterød T, Dalen SM, Mortensen E, Solbu MD, Nalwoga H, Akslen LA, Blix ES, Haugnes HS (2025)
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study
Breast Cancer Res Treat (in press)
DOI 10.1007/s10549-025-07786-4, PubMed 40694191

Publications 2022

Lofterød T, Frydenberg H, Veierød MB, Jenum AK, Reitan JB, Wist EA, Thune I (2022)
The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: The Oslo ethnic breast cancer study
Acta Oncol, 61 (5), 649-657
DOI 10.1080/0284186X.2022.2053573, PubMed 35348396

Publications 2020

Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, Akslen LA, Reitan JB, Wilsgaard T, Thune I (2020)
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study
Breast Cancer Res Treat, 182 (1), 215-227
DOI 10.1007/s10549-020-05679-2, PubMed 32436147

Publications 2018

Lofterød T, Mortensen ES, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T, Eggen AE, McTiernan A, Aziz S, Wist EA, Stensvold A, Reitan JB, Akslen LA, Thune I (2018)
Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes
BMC Cancer, 18 (1), 654
DOI 10.1186/s12885-018-4568-2, PubMed 29902993

Publications 2016

Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, Akslen LA, McTiernan A (2016)
Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival
Breast Cancer Res Treat, 155 (2), 345-54
DOI 10.1007/s10549-015-3671-1, PubMed 26740213